{"nctId":"NCT03693989","briefTitle":"Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification","startDateStruct":{"date":"2018-10-04","type":"ACTUAL"},"conditions":["Cataract"],"count":178,"armGroups":[{"label":"PRO-145.","type":"EXPERIMENTAL","interventionNames":["Drug: Difluprednate 0.05%"]},{"label":"Prednefrin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prednefrin"]}],"interventions":[{"name":"Difluprednate 0.05%","otherNames":["PRO-145"]},{"name":"Prednefrin","otherNames":["Difluprednate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent.\n* Age ≥ 18 years.\n* Both sexes.\n* Postoperative cataract surgery by phacoemulsification. o That they have met the criteria for phacoemulsification and a classification of the lens opacity classification system (LOCS) III cataract of Opalescence of the nucleus (NO) ≥2 and Kernel color (NC) ≥2.\n\nExclusion Criteria:\n\n* Pregnant women, lactating or planning to get pregnant.\n* Women of reproductive age and who do not have a hormonal contraceptive method, intrauterine device or bilateral tubal obstruction.\n* Participation in another clinical research study ≤ 30 days before the baseline visit.\n* Have previously participated in this same study with the contralateral eye.\n* That they can not comply with their attendance at appointments or with all the requirements of the protocol.\n\nMedical and therapeutic criteria.\n\n* Surgery in both eyes in the same surgical shift.\n* Time\\> 24 hours after having surgery.\n* Intraocular lens placement outside the bag.\n* Presentation of rupture of the posterior capsule, with or without the presence of vitreous.\n* Carrying out an iridectomy, or lesion of the pupillary sphincter during phacoemulsification surgery.\n* Scheduled for surgical intervention in the contralateral eye during the study period.\n* History of glaucoma or ocular hypertension.\n* History of increased Intraocular pressure (IOP) with the use of steroids.\n* Intraocular pressure (IOP) ≥24.\n* History of uveitis.\n* Presence of corneal abrasion or corneal ulceration in the study eye.\n* Use of steroids or topical non steroidal anti inflammatory drugs, 24 hours prior to surgery and until the start of instillation of investigational drugs.\n* Use of anticoagulants, systemic steroids or immunomodulators in the last two weeks\n* Periocular injection of any steroid in the study eye 4 weeks before the start of the instillation of the investigational drugs.\n* Use of storage steroids 2 months prior to the start of instillation of investigational drugs.\n* Presence or suspicion of keratitis and / or viral, bacterial or fungal conjunctivitis.\n* Presence or suspicion of endophthalmitis.\n* Presence or suspicion of toxic syndrome of the anterior segment.\n* Severe corneal edema that does not allow assessment of the anterior chamber\n* Macular diseases.\n* Diabetes Mellitus with glycosylated hemoglobin (A1C) ≥ 6.5% (48 mmol / mol) or fasting glucose (no caloric intake by ≥ 8 hours) of ≥ 126 mg / dL (7.0 mmol / L).\n* Any disease or condition that requires the use of topical or systemic nonsteroidal anti-inflammatories (NSAIDs) during the time of intervention.\n* Any disease or condition that requires the use of steroids other than topical ophthalmic application.\n* Subjects with a single eye.\n* Any condition or disease that at the discretion of the principal investigator (IP) does not make the subject suitable for the study.\n* Known hypersensitivity to the components of the products under investigation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Visual Ability (VA)","description":"The VA will be evaluated basally, without refractive correction with the Snellen chart. Which will be located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The result of the Snellen fraction will be transformed to its decimal equivalent in LogMAR, ex. 20/20= 1.0, 20/25=0.8, 20/40= 0.5, 20/200= 1.0, etc. The subjects will be averaged by group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.1"},{"groupId":"OG001","value":"0.87","spread":"0.2"}]}]}]},{"type":"PRIMARY","title":"Adverse Events","description":"The evaluation of adverse events requires a questioning conducted by the principal investigator and the appropriate exploratory techniques for its detection.\n\nthe number of cases with adverse events will be reported per study arm","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Cellularity in the Anterior Chamber","description":"unit: degrees, Direct observation (Biomicroscopy).\n\nScale for anterior chamber cellularity. Grade/Number of cells\n\nGrade / Number of cells\n\n0 Any\n\n½ + 1-5\n\n1. \\+ 6-15\n2. \\+ 16-25\n3. \\+ 26-60\n4. \\+ More than 60\n\nthe cellularity will be measured according to the scale that is added next, considering as normal the degree 0, and abnormal any other degree.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"76","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Corneal Edema","description":"The evaluation of clinical edema will be evaluated by the Efron scale, which is a series of factorial sections of the cornea, including features such as grooves and folds. The Efron scale has a strong correlation with variations in intensity. The number will be reported according to the rating awarded.\n\nEfron Scale: 0 Normal, 1 very slight, 2 mild, 3 moderate and 4 severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"83","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Flare","description":"In the presence of intraocular inflammation, the increased permeability of the non-pigmented layer of the ciliary epithelium, the posterior epithelium of the iris and the vascular endothelium of the iris results in the accumulation of cells and proteins (visible to the examiner as flare) in the anterior chamber. Using a light beam of 0.2mm X 0.2mm directed obliquely to the anterior chamber with a forward inclination of the light source (slit lamp tower) the degree of flare and cellularity will be determined according to the group of work of standardization for the nomenclature of uveitis.\n\nFlare scale\n\n0 There is no flare\n\n1. \\+ Mild\n2. \\+ Moderate (iris and crystalline clearly visible)\n3. \\+ Marking (iris and crystalline slightly blurred)\n4. \\+ More than 60 (fibrin)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"86","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Central Thickness of the Retina","description":"By means of optical coherence tomography (OCT) the Retinal central thickness (GCR) will be measured. OCT is a noninvasive imaging test that uses light waves to take photographs of the cross section of the retina (the light-sensitive tissue that lines the back of the eye).With a OCT, each of the characteristic layers of the retina can be observed, allowing mapping and measuring its thickness a micrometer result will be obtained and the analysis will be carried out between groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"253.59","spread":"26.9"},{"groupId":"OG001","value":"263.38","spread":"36.4"}]}]}]},{"type":"SECONDARY","title":"Conjunctival Hyperemia","description":"Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity, we will use the Efron scale for conjunctival hyperemia.\n\n0 normal\n\n1. very slight\n2. mild\n3. moderate\n4. severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"73","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Intraocular Pressure","description":"Tonometry is the objective measure of Intraocular pressure, based primarily on the force required to flatten the cornea, or the degree of corneal indentation produced by a fixed force. Goldman's tonometry is based on the Imbert-Fick principle. the result will be expressed in millimeters of mercury and the comparison between groups will be carried out","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.88","spread":"3.0"},{"groupId":"OG001","value":"13.04","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Symptomatology Post Instillation","description":"The subject will be questioned if after applying the medication he felt burning, pruritus, a foreign body sensation and blurred vision.\n\nPresence or absence: it will be marked as present (1) or absent (0) for each of the symptoms questioned","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":85},"commonTop":["ocular burning","eye foreign body sensation","Blurred Vision","eye itching","red eye"]}}}